Using hospital registries in Australia to extend data availability on vulval cancer treatment and survival

• Published in: BMC cancer Vol. 18; no. 1; p. 858
• Main Authors: Roder, David, Davy, Margaret, Selva-Nayagam, Sid, Paramasivam, Sellvakumaram, Adams, Jacqui, Keefe, Dorothy, Olver, Ian, Miller, Caroline, Buckley, Elizabeth, Powell, Kate, Fusco, Kellie, Buranyi-Trevarton, Dianne, Oehler, Martin K
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.08.2018; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Analysis; Australia - epidemiology; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Combined Modality Therapy; Databases, Factual; Epidemiology; Female; Genital cancers; Hospitals; Hospitals, Public; Humans; Investigations; Middle Aged; Mortality; Neoplasm Grading; Neoplasm Staging; Odds Ratio; Population; Population Surveillance; Proportional Hazards Models; Public hospitals; Radiation therapy; Registries; Services; Socioeconomic Factors; Surgery; Survival; Treatment outcome; Trends; Vulval cancer stage treatment survival; Vulvar cancer; Vulvar Neoplasms - epidemiology; Vulvar Neoplasms - mortality; Vulvar Neoplasms - pathology; Vulvar Neoplasms - therapy; Australia; Canada; United Kingdom > UK; United States > US; Norway; England; South Australia Australia; Germany; Vulval cancer stage treatment survival
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4759-x

The value of hospital registries for describing treatment and survival outcomes for vulval cancer was investigated. Hospital registry data from four major public hospitals in 1984-2016 were used because population-based data lacked required treatment and outcomes data. Unlike population registries, the hospital registries had recorded FIGO stage, grade and treatment. Unadjusted and adjusted disease-specific survival and multiple logistic regression were used. Disease-specific survivals were explored using Kaplan-Meier product-limit estimates. Hazards ratios (HRs) were obtained from proportional hazards regression for 1984-1999 and 2000-2016. Repeat analyses were undertaken using competing risk regression. Five-year disease-specific survival was 70%, broadly equivalent to the five-year relative survivals reported for Australia overall (70%), the United Kingdom (70%), USA (72%), Holland (70%), and Germany (Munich) (68%). Unadjusted five-year survival tended to be lower for cancers diagnosed in 2000-2016 than 1984-1999, consistent with survival trends reported for the USA and Canada, but higher for 2000-2016 than 1984-1999 after adjusting for stage and other covariates, although differences were small and did not approach statistical significance (p ≥ 0.40). Surgery was provided as part of the primary course of treatment for 94% of patients and radiotherapy for 26%, whereas chemotherapy was provided for only 6%. Less extensive surgical procedures applied in 2000-2016 than 1984-1999 and the use of chemotherapy increased over these periods. Surgery was more common for early FIGO stages, and radiotherapy for later stages with a peak for stage III. Differences in treatment by surgery and radiotherapy were not found by geographic measures of remoteness and socioeconomic status in adjusted analyses, suggesting equity in service delivery. The data illustrate the complementary value of hospital-registry data to population-registry data for informing local providers and health administrations of trends in management and outcomes, in this instance for a comparatively rare cancer that is under-represented in trials and under-reported in national statistics. Hospital registries can fill an evidence gap when clinical data are lacking in population-based registries.